The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.
about
Tackling ALK in non-small cell lung cancer: the role of novel inhibitorsEGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancerNot all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategyThe steady progress of targeted therapies, promising advances for lung cancerRecent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCThird-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancerCancer Evolution and the Limits of Predictability in Precision Cancer MedicineNext-generation sequencing to guide cancer therapyHeterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma.Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitorsUnravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsMechanisms of resistance to EGFR-targeted drugs: lung cancerThird-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung CancerOsimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapyGeneration of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.Emerging Agents and New Mutations in EGFR-Mutant Lung CancerAZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung CancerWhacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancerCirculating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancerResisting Resistance: Targeted Therapies in Lung Cancer.Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms.Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapyProfile of rociletinib and its potential in the treatment of non-small-cell lung cancer.Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR.Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors.Targeting ALK: Precision Medicine Takes on Drug Resistance.Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First LineMolecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets.Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.
P2860
Q26740329-48F2C010-977E-4C44-B7A2-7F79B96C02D4Q26741998-94E29930-BC39-46A9-8F87-34C459DED355Q26744284-ACB1F5F0-7C18-46C7-9DD1-0B6938FF9BC8Q26746895-42082533-352A-409F-ABC4-5730BE772ED4Q26747276-55DEB154-1CAE-46F0-BBD2-B7AF6E428875Q26748851-70D10E68-AE01-499C-BA52-D54FF1CE6097Q26767415-09EAD034-E8C5-466B-9F98-484305BE8F67Q26801946-C1767E1A-01D1-46CB-9C56-79FE30F95BA2Q27853391-FF8F6B01-2A40-45AE-90A8-11898EB64DC1Q28069708-2BCDEB0E-34ED-4E02-90A4-643772EC5CC5Q28075291-CD8C3C02-E858-4594-BC6E-F79740DAF256Q28077415-2849188B-7CB2-4619-B463-17CFD47D598EQ33740707-C97A517B-4D29-4669-8132-BC70DF7AEF32Q33757134-92A644AF-2068-496B-AC4E-C4B406C606A2Q33829488-30CC1A8E-0C61-4498-9E19-A64E9551BEA4Q34484794-4D2F3D5D-B356-449D-A00B-A3B6231FE529Q34497467-263420DD-4FDE-4FAD-BCCD-7C1B71005831Q34550460-11088E60-3832-4690-B1A8-6EF1055FB19DQ35844624-F38317A6-2D19-440C-84C2-DD05F5315E04Q36427381-586B0843-6E3C-4CB7-906C-1549AF4C4A1AQ36586155-9CAA6E3B-52CC-43D2-A751-4A5F0E2DB603Q36801144-2B8CB114-31E7-47A1-A85E-F1715639DFE4Q37000646-4F4588B1-0C02-4A9E-9F73-F53753BAE701Q37085219-6ABC0F1E-17D4-4F15-8B49-01289D519E00Q37225463-ADA4EE47-0F8A-4B2B-82BB-EC7CDCD990DBQ37388238-4EA56E30-F40B-4647-9578-3470558D9FD5Q37637905-DC445AC0-EE66-4B43-8A31-299F1CEDA5CAQ37698613-ACDB9E79-E6E0-4898-9814-27402551A7A2Q37726138-EEA6047C-65BF-4786-A4BF-B23D63DEE63AQ38598893-9552D659-A02F-463A-887F-F5BB10FEE618Q38756349-3EC0F72C-CECB-4DD4-8F8C-0DD62BBB66BDQ38790929-5DA2A8AF-E985-4CD3-B1DF-CC378C80119CQ38838227-8645BC6D-6EC5-4642-B8B6-C11B190A9AD1Q38988061-8E4AAF2C-F2D2-4E04-985C-72A1CC945545Q38991958-CFAB328A-7FDA-4750-8129-140E56CCBC13Q39079553-C867F9FE-048A-470D-94E0-B90306F896E5Q39103431-B629F924-663B-4175-ADC2-4A4B1DEEE904Q39114552-E7DD3595-1AA0-40D5-8FEE-8C92ABCC2D15Q39172297-2D27FF00-02CF-4948-90DF-53526CA0F9FDQ39220897-BAA520F8-FE90-4132-912D-77BC262CEC9F
P2860
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
The Allelic Context of the C79 ...... bsequent Treatment Strategies.
@ast
The Allelic Context of the C79 ...... bsequent Treatment Strategies.
@en
type
label
The Allelic Context of the C79 ...... bsequent Treatment Strategies.
@ast
The Allelic Context of the C79 ...... bsequent Treatment Strategies.
@en
prefLabel
The Allelic Context of the C79 ...... bsequent Treatment Strategies.
@ast
The Allelic Context of the C79 ...... bsequent Treatment Strategies.
@en
P2093
P2860
P1476
The Allelic Context of the C79 ...... bsequent Treatment Strategies.
@en
P2093
Angel R Garcia
Elizabeth L Lockerman
Haichuan Hu
Hillary E Mulvey
Jeffrey A Engelman
Lecia V Sequist
Matthew J Niederst
Zofia Piotrowska
P2860
P304
P356
10.1158/1078-0432.CCR-15-0560
P407
P577
2015-05-11T00:00:00Z